Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;49(7):2300-2309.
doi: 10.1007/s00259-022-05785-x. Epub 2022 Apr 11.

Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre

Ken Herrmann  1   2 , Luca Giovanella  3 , Andrea Santos  4 , Jonathan Gear  5 , Pinar Ozgen Kiratli  6 , Jens Kurth  7 , Ana M Denis-Bacelar  8 , Roland Hustinx  9   10 , Marianne Patt  11 , Richard L Wahl  12 , Diana Paez  13 , Francesco Giammarile  13 , Hossein Jadvar  14 , Neeta Pandit-Taskar  15 , Munir Ghesani  16 , Jolanta Kunikowska  17
Affiliations

Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre

Ken Herrmann et al. Eur J Nucl Med Mol Imaging. 2022 Jun.

Abstract

The theranostics concept using the same target for both imaging and therapy dates back to the middle of the last century, when radioactive iodine was first used to treat thyroid diseases. Since then, radioiodine has become broadly established clinically for diagnostic imaging and therapy of benign and malignant thyroid disease, worldwide. However, only since the approval of SSTR2-targeting theranostics following the NETTER-1 trial in neuroendocrine tumours and the positive outcome of the VISION trial has theranostics gained substantial attention beyond nuclear medicine. The roll-out of radioligand therapy for treating a high-incidence tumour such as prostate cancer requires the expansion of existing and the establishment of new theranostics centres. Despite wide global variation in the regulatory, financial and medical landscapes, this guide attempts to provide valuable information to enable interested stakeholders to safely initiate and operate theranostics centres. This enabling guide does not intend to answer all possible questions, but rather to serve as an overarching framework for multiple, more detailed future initiatives. It recognizes that there are regional differences in the specifics of regulation of radiation safety, but common elements of best practice valid globally.

Keywords: Nuclear medicine; PRRT; PSMA; Radionuclide theranostics; Theranostics.

PubMed Disclaimer

Conflict of interest statement

KH reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, all outside the submitted work. LG reports personal fees from Roche Diagnostics and SNIBE for advisory board participation, and research support from Roche Diagnostics., all outside the submitted work. AMDB is supported by the National Measurement System of the UK Department for Business, Energy and Industrial Strategy. RLW has research contracts from Siemens, Bayer, Actinium Pharmaceuticals, and serves (with compensation) on the scientific advisory boards of Seno Medical and Clarity Pharmaceuticals. HJ serves on the advisory board of Radiomedix, is a consultant to Bayer and Blue Earth Diagnostics, an investigator for ImaginAb, and on the speaker's bureau of Lantheus. MG reports fee for speakers bureau of Novartis, Blue Earth and Ionetix (not active currently). The remaining authors have no relevant conflict of interest to declare with regards to this comment.

Republished in

  • Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center.
    Herrmann K, Giovanella L, Santos A, Gear J, Ozgen Kiratli P, Kurth J, Denis-Bacelar AM, Hustinx R, Patt M, Wahl RL, Paez D, Giammarile F, Jadvar H, Pandit-Taskar N, Ghesani M, Kunikowska J. Herrmann K, et al. J Nucl Med. 2022 Dec;63(12):1836-1843. doi: 10.2967/jnumed.122.264321. Epub 2022 Apr 21. J Nucl Med. 2022. PMID: 35450957

References

    1. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329(7):459–465. doi: 10.1056/NEJM199308123290703. - DOI - PubMed
    1. Morschhauser F, Radford J, Van Hoof A, et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. J Clin Oncol. 2013;31(16):1977–83. doi: 10.1200/JCO.2012.45.6400. - DOI - PubMed
    1. Zippel C, Giesel FL, Kratochwil C, et al. PSMA radioligand therapy could pose infrastructural challenges for nuclear medicine: results of a basic calculation for the capacity planning of nuclear medicine beds in the German hospital sector. Nuklearmedizin. 2021;60(3):216–223 - PubMed
    1. Czernin J, Sonni I, Razmaria A, Calais J. The future of nuclear medicine as an independent specialty. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019;60(Suppl 2):3S–12S. doi: 10.2967/jnumed.118.220558. - DOI - PubMed
    1. Radiation Protection and Safety of Radiation Sources . International Basic Safety Standards. Vienna: INTERNATIONAL ATOMIC ENERGY AGENCY; 2014.

Substances